NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) between February 27, 2025, to May 26, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Rondolph Ho v. Rocket Pharmaceuticals, Inc., et al. (Case No. 3:25-cv-10049) has been commenced in the United States District Court ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that PepGen and its executives made false statements regarding the effectiveness and safety of PGN-EDO51, leading to an overstatement of its clinical and commercial prospects [5]. - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][3]. - There is an August 11, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against PepGen [3]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [6][7]. - A clinical hold notice from the FDA on December 16, 2024, raised concerns about the CONNECT2 study, resulting in a 3.63% decline in stock price [8][9]. - Following updates on safety concerns and a temporary pause of the CONNECT2 study on March 4, 2025, PepGen's stock fell by 18.86% [10][11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12].

Core Viewpoint - Fortrea Holdings Inc. is facing potential legal claims due to allegations of misleading statements regarding its financial performance and business model, particularly related to its Pre-Spin Projects and cost savings from exiting Transitional Service Agreements (TSAs) [4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Fortrea and has set an August 1, 2025 deadline for investors to seek lead plaintiff status in a federal securities class action [2]. - Investors who suffered losses in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact the firm to discuss their legal options [1]. Group 2: Financial Performance and Stock Price Impact - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting TSAs, leading to inflated EBITDA targets for 2025 [4]. - Following a downgrade by Jefferies on September 25, 2024, Fortrea's stock price fell by $2.73, or 12.29%, closing at $19.48 per share [5]. - A subsequent downgrade by Baird on December 6, 2024, after the cancellation of two conferences, resulted in a further stock price decline of $1.90, or 8.06%, closing at $21.67 per share [6]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a significant stock price drop of $3.47, or 25.05%, closing at $10.38 per share [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and IPO funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against Red Cat - The complaint alleges that Red Cat and its executives made false and misleading statements regarding the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract [5][8]. - It is claimed that the production capacity of the Salt Lake City Facility was overstated, with management initially suggesting it could produce thousands of drones per month, but later revealing it could only produce 100 drones per month [9][10]. - The SRR Contract was initially suggested to be worth potentially hundreds of millions to over a billion dollars, but subsequent reports indicated it was only valued at approximately $20 million to $25 million [12][13]. Group 2: Financial Impact and Stock Performance - Following the disclosure of the actual production capacity and the status of the Salt Lake City Facility, Red Cat's stock price fell by 8.93% to close at $1.02 per share on July 28, 2023 [10]. - After reporting losses per share of $0.17 and revenue of $2.8 million, which missed consensus estimates, the stock price dropped by 25.32% to close at $2.36 per share on September 25, 2024 [11]. - A significant drop of 21.54% occurred after the Kerrisdale Report was published, which questioned the company's previous claims, leading to a stock price of $8.56 per share on January 17, 2025 [14]. Group 3: Company Background and Legal Context - Red Cat was selected by the U.S. Department of Defense's Defense Innovation Unit to compete in the SRR Program, aimed at providing small, portable drones to Army platoons [6]. - The law firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - Investors who suffered losses are encouraged to contact the firm for discussions regarding their legal rights and options [1][16].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending to closed platforms, where the company's capabilities were limited [5]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, impacting the monetization of DoubleVerify's high-margin Activation Services [5]. - Competitors were reportedly better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's competitive stance and profitability [5]. - The company allegedly overbilled customers for ad impressions served to declared bots, and its risk disclosures were misleading, characterizing known adverse facts as mere possibilities [5]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a 36% drop in DoubleVerify's stock price following disappointing earnings and the suspension of services by a major customer [6]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [7]. - Faruqi & Faruqi encourages anyone with information regarding DoubleVerify's conduct to come forward, including whistleblowers and former employees [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BigBear.ai To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in BigBear.ai between March 31, 2022 and March 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Civitas Resources, Inc. due to allegations of misleading statements and failure to disclose critical information regarding the company's financial and operational status [2][4]. Group 1: Allegations Against Civitas - The complaint alleges that Civitas and its executives violated federal securities laws by making false and misleading statements, including the likelihood of a significant reduction in oil production in 2025 [4]. - It is claimed that increasing oil production would necessitate acquiring additional acreage, leading to significant debt and asset sales [4]. - The company's financial condition is said to require disruptive cost-reduction measures, including a substantial workforce reduction [4]. - As a result, Civitas's business and financial prospects were overstated, making public statements materially false and misleading [4]. Group 2: Financial Performance and Market Reaction - On February 24, 2025, Civitas reported fourth quarter and full year financial results that missed consensus estimates for revenue and non-GAAP EPS [5]. - The company announced a 10% workforce reduction and the immediate termination of its Chief Operating Officer and Chief Transformation Officer [5]. - Following this news, Civitas's stock price dropped by $8.95, or 18.2%, closing at $40.35 per share on February 25, 2025, resulting in investor losses [5]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses in Civitas are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is a deadline of July 1, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Civitas [2][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Civitas's conduct [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [4]. - Specific issues highlighted include the operational inefficiencies of the SmartDose device, which was expected to be a high-margin growth product but instead diluted profit margins [4]. - The allegations also mention the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers, due to these margin pressures [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [5]. - Following this announcement, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [5]. Group 3: Legal Proceedings - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options, with a deadline of July 7, 2025, to seek the role of lead plaintiff in the federal securities class action [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Red Cat To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ ...